Evidence map›Paper›PMID 41344324›Full record

ArticleCell reports methods2026

FAME-CRISPR improves CRISPR-Cas9 genome editing via HDAC inhibition and engineered virus-like particle delivery.

Mahbod Djamshidi, Alexander Hill, Katayoun Heshmatzad, Jethro Langley, Hokan Krowicki, Motamed Ali, Yang Yang, Ryota Tanida, Mohamed Faizal Abdul-Careem, Pierre Billon and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports methods, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Mahbod DjamshidiRobson DNA Sciences Centre, Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB, Canada; Alberta Children's Hospital Research Institute, University of Calgary, Calgary, AB, Canada; Arthur JE Childs Comprehensive Cancer Institute, University of Calgary, Calgary, AB, Canada; Departments of Biochemistry and Molecular Biology, University of Calgary, Calgary, AB, Canada; Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.
Alexander HillArthur JE Childs Comprehensive Cancer Institute, University of Calgary, Calgary, AB, Canada.
Katayoun HeshmatzadRobson DNA Sciences Centre, Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB, Canada; Arthur JE Childs Comprehensive Cancer Institute, University of Calgary, Calgary, AB, Canada; Departments of Biochemistry and Molecular Biology, University of Calgary, Calgary, AB, Canada; Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.
Jethro LangleyRobson DNA Sciences Centre, Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB, Canada; Arthur JE Childs Comprehensive Cancer Institute, University of Calgary, Calgary, AB, Canada; Departments of Biochemistry and Molecular Biology, University of Calgary, Calgary, AB, Canada; Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.
Hokan KrowickiRobson DNA Sciences Centre, Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB, Canada; Arthur JE Childs Comprehensive Cancer Institute, University of Calgary, Calgary, AB, Canada; Departments of Biochemistry and Molecular Biology, University of Calgary, Calgary, AB, Canada; Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.
Motamed AliDepartments of Ecosystem and Public Health, University of Calgary, Calgary, AB, Canada; Faculty of Veterinary Medicine, University of Calgary, Calgary, AB, Canada.
Yang YangRobson DNA Sciences Centre, Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB, Canada; Arthur JE Childs Comprehensive Cancer Institute, University of Calgary, Calgary, AB, Canada; Departments of Biochemistry and Molecular Biology, University of Calgary, Calgary, AB, Canada; Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.
Ryota TanidaRobson DNA Sciences Centre, Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB, Canada; Alberta Children's Hospital Research Institute, University of Calgary, Calgary, AB, Canada; Arthur JE Childs Comprehensive Cancer Institute, University of Calgary, Calgary, AB, Canada; Departments of Biochemistry and Molecular Biology, University of Calgary, Calgary, AB, Canada; Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.
Mohamed Faizal Abdul-CareemDepartments of Ecosystem and Public Health, University of Calgary, Calgary, AB, Canada; Faculty of Veterinary Medicine, University of Calgary, Calgary, AB, Canada.
Pierre BillonRobson DNA Sciences Centre, Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB, Canada; Alberta Children's Hospital Research Institute, University of Calgary, Calgary, AB, Canada; Arthur JE Childs Comprehensive Cancer Institute, University of Calgary, Calgary, AB, Canada; Departments of Biochemistry and Molecular Biology, University of Calgary, Calgary, AB, Canada; Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.
Karl RiabowolRobson DNA Sciences Centre, Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB, Canada; Alberta Children's Hospital Research Institute, University of Calgary, Calgary, AB, Canada; Arthur JE Childs Comprehensive Cancer Institute, University of Calgary, Calgary, AB, Canada; Departments of Biochemistry and Molecular Biology, University of Calgary, Calgary, AB, Canada; Department of Oncology, University of Calgary, Calgary, AB, Canada; Cumming School of Medicine, University of Calgary, Calgary, AB, Canada. Electronic address: karl@ucalgary.ca.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

CRISPR-mediated gene editing using engineered virus-like particles (eVLPs) can achieve high efficiency, but performance varies with reduced effectiveness often seen in primary cells or when generating polyclonal models at scale. We developed a faster, accurate and 4-fold more efficient CRISPR-Cas9 (FAME-CRISPR) method using pan-histone deacetylase inhibitors with eVLP transduction compared to previous reports using other histone deacetylase inhibitors. Combined optimization of pan-HDACi treatment with eVLP enhanced double-strand break (DSB)-mediated CRISPR and base editing gave significantly edited populations within 2- to 3-cell mean population doublings, reducing the need for post-editing selection in immortalized cancer cells and in primary diploid fibroblasts that have limited replicative lifespans.

Indexed as

CRISPR-Cas SystemsGene EditingHistone Deacetylase InhibitorsVirionDNA Breaks, Double-StrandedHEK293 CellsHumansHistone Deacetylase Inhibitorsbase editingchromatinCP: biotechnologyCP: geneticsCRISPR-Cas9eVLPsgene editingHDACiimproved efficiencyoptimization

Identifiers

PMID41344324
PMCPMC12853189

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.